BETA

Beta Drugs Share PriceBeta Drugs

₹1,177.00
9.1 (0.78%)
As on 30 November, 2023 | 20:42 BSE: 531481 NSE: BETAISIN: INE351Y01019

Beta Drugs Performance

Day Range

  • Low 1,170.00
  • High 1,200.00
₹ 1,177.00

52 Week Range

  • Low 600.00
  • High 1,270.00
₹ 1,177.00
  • Open Price1,180.00
  • Previous Close1,167.90
  • Volume2000

Start SIP in Beta Drugs

Start SIP

Beta Drugs Share Price

  • Over 1 Month 21.18%
  • Over 3 Month 17.13%
  • Over 6 Month 59.05%
  • Over 1 Year 62.54%

Beta Drugs Key Statistics

P/E Ratio
PEG Ratio
Market Cap Cr 1,132
Price to Book Ratio 9.2
EPS 19.6
Dividend 0
Relative Strength Index 61.35
Money Flow Index 56.08
MACD Signal 48.14
Average True Range 46.91

Beta Drugs Investment Rating

  • Master Rating:
  • Beta Drugs has an operating revenue of Rs. 617.88 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 18% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 39% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Beta Drugs Financials
Indicator
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 159126
Operating Expenses Annual Cr 127100
Operating Profit Annual in Cr 3125
Depreciation Cr 65
Interest Annual Cr 10
Tax Annual Cr 66
Net Profit Annual Cr 1914
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 19
Cash from Investing Activity Annual Cr -13
Cash from Financing Annual Activity Cr 1
Net Cash Flow Annual Cr 7
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 9677
Fixed Assets Annual Cr 3534
Total Non Current Assets Annual Cr 4948
Total Current Assets Annual Cr 8563
Total Assets Annual Cr 134111
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 10081
ROE Annual % 2018
ROCE Annual % 2524
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2021
Indicator
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 228185
Operating Expenses Annual Cr 174141
Operating Profit Annual in Cr 5343
Depreciation Cr 107
Interest Annual Cr 22
Tax Annual Cr 109
Net Profit Annual Cr 3125
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 30
Cash from Investing Activity Annual Cr -22
Cash from Financing Annual Activity Cr -1
Net Cash Flow Annual Cr 7
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 12392
Fixed Assets Annual Cr 6355
Total Non Current Assets Annual Cr 7161
Total Current Assets Annual Cr 12897
Total Assets Annual Cr 198158
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 12896
ROE Annual % 2527
ROCE Annual % 3233
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2424

Beta Drugs Technicals

EMA & SMA

Current Price
₹1,177.00
9.1 (0.78%)
pointer
  • Bullish Moving Average
  • ___
  • 15
  • Bearish Moving Average
  • ___
  • 1
  • 20 Day
  • ₹1,135.45
  • 50 Day
  • ₹1,063.31
  • 100 Day
  • ₹984.87
  • 200 Day
  • ₹892.19
  • 20 Day
  • ₹1,140.42
  • 50 Day
  • ₹1,047.56
  • 100 Day
  • ₹961.68
  • 200 Day
  • ₹839.03

Beta Drugs Resistance and Support

PIVOT
₹1,182.34
Resistance
First Resistance 1,194.67
Second Resistance 1,212.33
Third Resistance 1,224.67
RSI 61.35
MFI 56.08
MACD Single Line 48.14
MACD 43.36
Support
First Resistance 1,164.67
Second Resistance 1,152.33
Third Resistance 1,134.67

Beta Drugs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 2,000 180,000 90
Week 3,050 257,512 84.43
1 Month 5,976 458,075 76.65
6 Month 5,726 449,105 78.43

Beta Drugs Result Highlights

Beta Drugs Synopsis

NSE-Medical-Diversified

Beta Drugs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 157.87 Cr. and Equity Capital is Rs. 9.61 Cr. for the Year ended 31/03/2023. Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969.
Market Cap 1,139
Sales 158
Shares in Float 0.32
No of funds 2
Yield
Book Value 11.67
U/D Vol ratio 1.1
LTDebt / Equity 4
Alpha 0.17
Beta 0.56

Beta Drugs

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 66.73%66.73%66.73%66.71%
Foreign Portfolio Investors 0.32%0.29%0.29%0.29%
Individual Investors 22.37%22.24%22.52%22.6%
Others 10.58%10.74%10.46%10.4%

Beta Drugs Management

Name Designation
Mr. Rahul Batra Chairman & Managing Director
Mr. Varun Batra Joint Managing Director
Mr. Balwant Singh Whole Time Director
Mrs. Seema Chopra Whole Time Director
Mr. Ashutosh Shukla Whole Time Director
Mr. Manmohan Khanna Independent Director
Mr. Rohit Parti Independent Director

Beta Drugs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Beta Drugs Corporate Action

Date Purpose Remarks
2023-11-07 Quarterly Results & Others To consider the Migration of the Equity shares of the Company from Emerge-SME Platform of National Stock Exchange of India Limited ( NSE Emerge ) to the Main board of NSE and BSE.
2023-05-08 Audited Results
2022-10-27 Quarterly Results
2022-04-27 Audited Results
2021-10-25 Quarterly Results

Beta Drugs FAQs

What is Share Price of Beta Drugs ?

Beta Drugs share price is ₹1,177 As on 30 November, 2023 | 20:28

What is the Market Cap of Beta Drugs ?

The Market Cap of Beta Drugs is ₹1131.5 Cr As on 30 November, 2023 | 20:28

What is the P/E ratio of Beta Drugs ?

The P/E ratio of Beta Drugs is As on 30 November, 2023 | 20:28

What is the PB ratio of Beta Drugs ?

The PB ratio of Beta Drugs is 9.2 As on 30 November, 2023 | 20:28

Q2FY23